These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
43. Diagnostic Performance of Electronic Noses in Cancer Diagnoses Using Exhaled Breath: A Systematic Review and Meta-analysis. Scheepers MHMC; Al-Difaie Z; Brandts L; Peeters A; van Grinsven B; Bouvy ND JAMA Netw Open; 2022 Jun; 5(6):e2219372. PubMed ID: 35767259 [TBL] [Abstract][Full Text] [Related]
44. Metabolomics of volatile organic compounds in cystic fibrosis patients and controls. Robroeks CM; van Berkel JJ; Dallinga JW; Jöbsis Q; Zimmermann LJ; Hendriks HJ; Wouters MF; van der Grinten CP; van de Kant KD; van Schooten FJ; Dompeling E Pediatr Res; 2010 Jul; 68(1):75-80. PubMed ID: 20351658 [TBL] [Abstract][Full Text] [Related]
45. Preliminary method for profiling volatile organic compounds in breath that correlate with pulmonary function and other clinical traits of subjects diagnosed with cystic fibrosis: a pilot study. Woollam M; Siegel AP; Grocki P; Saunders JL; Sanders DB; Agarwal M; Davis MD J Breath Res; 2022 Feb; 16(2):. PubMed ID: 35120338 [TBL] [Abstract][Full Text] [Related]
46. Exhaled breath analysis in adult patients with cystic fibrosis by real-time proton mass spectrometry. Mustafina M; Silantyev A; Krasovskiy S; Chernyak A; Naumenko Z; Suvorov A; Gognieva D; Abdullaev M; Bektimirova A; Bykova A; Dergacheva V; Betelin V; Kopylov P Clin Chim Acta; 2024 Jun; 560():119733. PubMed ID: 38777246 [TBL] [Abstract][Full Text] [Related]
47. Post-COVID syndrome screening through breath analysis using electronic nose technology. V R N; Mohapatra AK; V K U; Lukose J; Kartha VB; Chidangil S Anal Bioanal Chem; 2022 May; 414(12):3617-3624. PubMed ID: 35303135 [TBL] [Abstract][Full Text] [Related]
48. Breath profiles by electronic nose correlate with systemic markers but not ozone response. Biller H; Holz O; Windt H; Koch W; Müller M; Jörres RA; Krug N; Hohlfeld JM Respir Med; 2011 Sep; 105(9):1352-63. PubMed ID: 21439804 [TBL] [Abstract][Full Text] [Related]
49. Feasibility study on exhaled-breath analysis by untargeted Selected-Ion Flow-Tube Mass Spectrometry in children with cystic fibrosis, asthma, and healthy controls: Comparison of data pretreatment and classification techniques. Segers K; Slosse A; Viaene J; Bannier MAGE; Van de Kant KDG; Dompeling E; Van Eeckhaut A; Vercammen J; Vander Heyden Y Talanta; 2021 Apr; 225():122080. PubMed ID: 33592793 [TBL] [Abstract][Full Text] [Related]
50. Non-invasive breath monitoring with eNose does not improve glucose diagnostics in critically ill patients in comparison to continuous glucose monitoring in blood. Leopold JH; Bos LDJ; Colombo C; Sterk PJ; Schultz MJ; Abu-Hanna A J Breath Res; 2017 Apr; 11(2):026002. PubMed ID: 28260695 [TBL] [Abstract][Full Text] [Related]
51. Exhaled and nasal nitric oxide in relation to lung function, blood cell counts and disease characteristics in cystic fibrosis. Krantz C; Janson C; Hollsing A; Alving K; Malinovschi A J Breath Res; 2017 Mar; 11(2):026001. PubMed ID: 28220034 [TBL] [Abstract][Full Text] [Related]
52. Diagnostic performance of eNose technology in COVID-19 patients after hospitalization. van Raaij BFM; Veltman JD; Hameete JF; Stöger JL; Geelhoed JJM BMC Pulm Med; 2023 Apr; 23(1):134. PubMed ID: 37081422 [TBL] [Abstract][Full Text] [Related]
53. The analysis of volatile organic compounds biomarkers for lung cancer in exhaled breath, tissues and cell lines. Wang Y; Hu Y; Wang D; Yu K; Wang L; Zou Y; Zhao C; Zhang X; Wang P; Ying K Cancer Biomark; 2012; 11(4):129-37. PubMed ID: 23144150 [TBL] [Abstract][Full Text] [Related]
54. Exhaled breath analysis by electronic nose in airways disease. Established issues and key questions. Fens N; van der Schee MP; Brinkman P; Sterk PJ Clin Exp Allergy; 2013 Jul; 43(7):705-15. PubMed ID: 23786277 [TBL] [Abstract][Full Text] [Related]
55. On the importance of accurate quantification of individual volatile metabolites in exhaled breath. Smith D; Španěl P J Breath Res; 2017 Nov; 11(4):047106. PubMed ID: 28635619 [TBL] [Abstract][Full Text] [Related]
56. Association between exhaled inflammatory markers and asthma control in children. Van Vliet D; Smolinska A; Jöbsis Q; Rosias PP; Muris JW; Dallinga JW; van Schooten FJ; Dompeling E J Breath Res; 2016 Feb; 10(1):016014. PubMed ID: 26893372 [TBL] [Abstract][Full Text] [Related]
57. Breathomics from exhaled volatile organic compounds in pediatric asthma. Neerincx AH; Vijverberg SJH; Bos LDJ; Brinkman P; van der Schee MP; de Vries R; Sterk PJ; Maitland-van der Zee AH Pediatr Pulmonol; 2017 Dec; 52(12):1616-1627. PubMed ID: 29082668 [TBL] [Abstract][Full Text] [Related]
58. Altered exhaled biomarker profiles in children during and after rhinovirus-induced wheeze. van der Schee MP; Hashimoto S; Schuurman AC; van Driel JS; Adriaens N; van Amelsfoort RM; Snoeren T; Regenboog M; Sprikkelman AB; Haarman EG; van Aalderen WM; Sterk PJ Eur Respir J; 2015 Feb; 45(2):440-8. PubMed ID: 25323245 [TBL] [Abstract][Full Text] [Related]
59. Exhaled volatile organic compounds predict exacerbations of childhood asthma in a 1-year prospective study. Robroeks CM; van Berkel JJ; Jöbsis Q; van Schooten FJ; Dallinga JW; Wouters EF; Dompeling E Eur Respir J; 2013 Jul; 42(1):98-106. PubMed ID: 23645402 [TBL] [Abstract][Full Text] [Related]
60. An electronic nose in the discrimination of patients with asthma and controls. Dragonieri S; Schot R; Mertens BJ; Le Cessie S; Gauw SA; Spanevello A; Resta O; Willard NP; Vink TJ; Rabe KF; Bel EH; Sterk PJ J Allergy Clin Immunol; 2007 Oct; 120(4):856-62. PubMed ID: 17658592 [TBL] [Abstract][Full Text] [Related] [Previous] [Next] [New Search]